Clinical Trial: A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy

U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07341828) titled 'A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy' on Jan. 06.

Brief Summary: This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with central nervous system autoimmune diseases refractory to standard therapy

Study Start Date: Feb., 2026

Study Type: INTERVENTIONAL

Condition: Multiple Sclerosis (MS) Neuromyelitis Optica Spectrum Disorders (NMOSD) Autoimmune Encephalitis Stiff Person Syndrome

Intervention: BIOLOGICAL: CD20/BCMA-directed CA...